• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases.

作者信息

Kochar Bharati, Kalasapudi Lakshman, Ufere Nneka N, Nipp Ryan D, Ananthakrishnan Ashwin N, Ritchie Christine S

机构信息

Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Inflamm Bowel Dis. 2021 Aug 19;27(9):1541-1543. doi: 10.1093/ibd/izab052.

DOI:10.1093/ibd/izab052
PMID:33705536
Abstract
摘要

相似文献

1
Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases.用于治疗炎症性肠病的药物随机对照试验中纳入和分析老年人的系统评价
Inflamm Bowel Dis. 2021 Aug 19;27(9):1541-1543. doi: 10.1093/ibd/izab052.
2
[Diet therapy in chronic inflammatory bowel disease: results from meta-analysis and randomized controlled trials].[慢性炎症性肠病的饮食疗法：荟萃分析和随机对照试验的结果]
Praxis (Bern 1994). 2002 Nov 20;91(47):2041-9. doi: 10.1024/0369-8394.91.47.2041.
3
Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.生物疗法和小分子药物对炎症性肠病患者主要不良心血管事件风险的影响：随机对照试验的系统评价和荟萃分析
Expert Rev Gastroenterol Hepatol. 2023 May;17(5):469-477. doi: 10.1080/17474124.2023.2194631. Epub 2023 Apr 10.
4
[Probiotics in inflammatory bowel disease: controlled trials and perspectives].[炎症性肠病中的益生菌：对照试验与展望]
Therapie. 2004 Jan-Feb;59(1):83-7. doi: 10.2515/therapie:2004017.
5
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
6
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
7
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.英夫利昔单抗与维得利珠单抗治疗炎症性肠病患者的疗效和安全性比较：系统评价和荟萃分析。
BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1.
8
Review of Saccharomyces boulardii as a treatment option in IBD.布拉氏酵母菌在炎症性肠病治疗中的应用评价。
Immunopharmacol Immunotoxicol. 2018 Dec;40(6):465-475. doi: 10.1080/08923973.2018.1469143. Epub 2018 May 17.
9
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率：基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
10
Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment.布地奈德：为炎症性肠病治疗探索新方法
Curr Med Chem. 2008;15(24):2527-35. doi: 10.2174/092986708785909049.

引用本文的文献

1
Clin-STAR Corner: Practice-Changing Advances at the Interface of Gastroenterology & Geriatrics.临床之星专栏：胃肠病学与老年医学交叉领域的变革性进展
J Am Geriatr Soc. 2025 Apr 9. doi: 10.1111/jgs.19467.
2
Existential Reflections by Older Adults With Inflammatory Bowel Diseases on Medical and Surgical Treatments.炎症性肠病老年患者对药物及手术治疗的存在主义思考
Am J Gastroenterol. 2025 Apr 7;120(8):1829-1838. doi: 10.14309/ajg.0000000000003475.
3
Older Adults with Inflammatory Bowel Disease Epidemiology in the United States: 2000-2021.
美国2000 - 2021年老年炎症性肠病流行病学
Dig Dis Sci. 2025 Mar 19. doi: 10.1007/s10620-025-08976-2.
4
A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel Diseases.老年炎症性肠病患者的老年综合征及评估综述
Clin Gastroenterol Hepatol. 2025 Jun;23(7):1088-1101. doi: 10.1016/j.cgh.2024.09.042. Epub 2025 Mar 11.
5
Frailty: An Underappreciated Risk Factor for IBD Complications.衰弱：IBD 并发症的一个被低估的风险因素。
Curr Gastroenterol Rep. 2024 Dec;26(12):315-322. doi: 10.1007/s11894-024-00945-5. Epub 2024 Sep 5.
6
Pharmacoequity in Older Patients With Inflammatory Bowel Disease.老年炎症性肠病患者的药物公平性
Gastroenterol Hepatol (N Y). 2024 Aug;20(8):494-503.
7
A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease.炎症性肠病现代治疗时代患者关切问题的研究
Inflamm Bowel Dis. 2025 Jun 13;31(6):1595-1604. doi: 10.1093/ibd/izae197.
8
Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets.美沙拉嗪在成人和老年溃疡性结肠炎患者中的疗效相似：1600毫克与400毫克片剂随机非劣效性试验的事后分析
Inflamm Bowel Dis. 2025 Apr 10;31(4):975-982. doi: 10.1093/ibd/izae123.
9
Prevalence and Appropriateness of Polypharmacy in Older Adults with Inflammatory Bowel Diseases.炎症性肠病老年患者多重用药的患病率及合理性
Dig Dis Sci. 2024 Mar;69(3):766-774. doi: 10.1007/s10620-023-08250-3. Epub 2024 Jan 25.
10
Differences in Management and Outcomes of Older and Younger Adults with Acute Severe Ulcerative Colitis.急性重症溃疡性结肠炎老年和青年患者的管理及结局差异
J Crohns Colitis. 2024 Apr 23;18(4):570-577. doi: 10.1093/ecco-jcc/jjad183.